ADC药物研发现状.xls

Title Originator Highest Dev Status
111In-capromab pendetide Cytogen Corp Launched
111In-imciromab pentetate Janssen Biotech Inc Launched
131I-chTNT-1/B Peregrine Pharmaceuticals Inc Launched
131I-metuximab Fourth Military Medical University PLA Launched
brentuximab vedotin Seattle ics Inc Launched
gemtuzumab Wyeth Research Launched
ibritumomab tiuxetan IDEC Pharmaceuticals Corp Launched
trastuzumab emtansine Genentech Inc Launched
ATL-101, ATLAB Cornell University Phase 3 Clinical
inotuzumab ozogamicin Wyeth Research Phase 3 Clinical
oportuzumab monatox (intratumoral, head and neck cancer), Viventia University of Zurich Phase 3 Clinical
49 Navidea Biopharmaceuticals Inc Phase 3 Clinical
ABT-414 Abbott Laboratories Phase 2 Clinical
CDX-1401 Celldex Therapeutics Inc (pre-merger) Phase 2 Clinical
glembatumumab vedotin CuraGen Corp Phase 2 Clinical
LMB-2 National Cancer Institute Phase 2 Clinical
lorvotuzumab mertansine ImmunoGen Inc Phase 2 Clinical
moxetumomab pasudotox National Cancer Institute Phase 2 Clinical
oportuzumab monatox (intravesicular, bladder cancer), Viventia University of Zurich Phase 2 Clinical
PSMA-ADC Cytogen Corp Phase 2 Clinical
RG-7593 Genentech Inc Phase 2 Clinical
RG-7596 Genentech Inc Phase 2 Clinical
SAR-3419 ImmunoGen Inc Phase 2 Clinical
212-Pb-TCMC-trastuzumab National Cancer Institute Phase 1 Clinical